secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aktis Oncology, Inc. (AKTS)
CIK:        0002035832
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001193125-26-158944
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aktis Oncology appoints Glenn Gormley to board; two directors resign
--------------------------------------------------------------------

- Glenn Gormley, MD, PhD appointed independent director and co-chair of new Science and Technology Committee, effective April 15, 2026.
- Gormley, 72, previously Global Head of R&D at Daiichi Sankyo; over 30 years biopharma leadership.
- Received option for 37,866 shares vesting over three years; annual cash compensation $45,000 plus $15,000 for committee role.
- Helen S. Kim and Oleg Nodelman resign from board effective May 20, 2026; not due to any disagreement.
- Gormley joins as company advances clinical milestones in targeted radiopharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2035832/000119312526158944/0001193125-26-158944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2035832/000119312526158944/d110479d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-158944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer